PDL BioPharma Financials

PDL BioPharma Stock Summary

PDL BioPharma competes with Anheuser Busch, Vita Coco, Fair Isaac, Cedar Fair, and Fresh Grapes. PDL BioPharma, Inc. manages various patents in the United States and internationally. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada. PDL BioPharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 109 people.

PDL BioPharma Key Financial Ratios

Generally speaking, PDL BioPharma's financial ratios allow both analysts and investors to convert raw data from PDL BioPharma's financial statements into concise, actionable information that can be used to evaluate the performance of PDL BioPharma over time and compare it to other companies across industries. There are many critical financial ratios that investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that PDL BioPharma reports annually and quarterly.

PDL Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining PDL BioPharma's current stock value. Our valuation model uses many indicators to compare PDL BioPharma value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across PDL BioPharma competition to find correlations between indicators driving PDL BioPharma's intrinsic value. More Info.PDL BioPharma is considered to be number one stock in return on equity category among related companies. It is considered to be number one stock in return on asset category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value PDL BioPharma by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for PDL BioPharma's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the PDL BioPharma's earnings, one of the primary drivers of an investment's value.

Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.

If you are still planning to invest in PDL BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the PDL BioPharma's history and understand the potential risks before investing.